Abstract
Remarkable progress has been made in the treatment and outcome of adult acute lymphoblastic leukemia (ALL) over the past 3 decades. This progress is the result of an accumulation of a mosaic of knowledge and experience, which have led to a more profound understanding of the biology of the disease, and at the same time the development of new drugs and treatment strategies. Advances in the understanding of the biology has highlighted significant differences between childhood and adult ALL (e.g., high frequency of Philadelphia-positive ALL and low incidence of TEL-AML1-positive disease in adults) and thus explains at least partly the divergence of outcomes that is still observed between children and adults. Moreover, ALL is increasingly recognized as a group of heterogeneous disease entities with unique responses to therapy and prognosis. The combination of further cytogenetic-molecular dissection of ALL subtypes with the emergence of new and targeted therapies will thus continue to constitute the fundament upon which further progress will hopefully occur in adult ALL.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Kantarjian HM, O’Brien S, Smith TL, et al. (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18:547–561
Larson RA, Dodge RK, Burns CP, et al. (1995) A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood 85:2025–2037
Durrant IJ, Richards, SM, Prentice HG, et al. (2000) The Medical Research Council trials in adult acute lymphocytic leukemia. Hem Onc Clin North Am 14:1327–1352
Gökbuget N, Hoelzer D. (2002) Recent approaches in acute lymphoblastic leukemia in adults. Rev Clin Exp Hematol 6:114–141
Jones B, Freeman AI, Shuster JJ, et al. (1991) Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 19:269–275
Bostrom BC, Sensel MR, Sather HN, et al. (2003) Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the Children’s Cancer Group. Blood 101:3809–3817
Todeschini G, Tecchio C, Meneghini V, et al. (1998) Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol on high induction dose of daunorubicin. Leukemia 12:144–148
Larson RA. (2004) The US trials in adult acute lymphoblastic leukemia. Ann Hematol 83(Suppl 1):S127–128
Weiss M, Maslak P, Feldman E, et al. (1996) Cytarabine with high dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia (ALL) without the use of vincristine or prednisone. J Clin Oncol 14:2480–2485
Weiss M (2001) Induction therapyof adult acute lymphocytic leukemia without the use of vincristine or prednisone. Hem Onc Clin North Am 15:1–7
Larson RA, Dodge RK, Linker CA, et al. (1998) A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 92:1556–1564
Hoelzer D. (1996) Acute lymphoblastic leukemia: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87:495–508
Thomas D, Cortes J, O’Brien S, et al. (1999) Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461–2470
Thiebault A, Vernant JP, Degos L, et al. (2000) Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hem Onc Clin North Am 14:1353–1366
Rowe JM, Richards S, Burnett AK, et al. (2001) Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 98:481a
Childhood ALL Cooperative Group. (1996) Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12000 randomized children. Lancet 347:1783–1788
Mandelli F, Annino L, Rotoli B (1996) The GIMEMA ALL 0183 trial: Analysis of 10-year follow-up. Br J Haematol 92:665–672
Thomas DA, Kantarjian HM (2001) Lymphoblastic lymphoma. Hem Onc Clin North Am 15:51–95
Thomas DA, Cortes J, O’Brien SM, et al. (2000) Significance of CD20 positivity in de novo acute lymphocytic leukemia (ALL). Blood 96:109a
Thomas DA, Cortes J, Giles FJ, et al. (2001) The modified hyper-CVAD regimen in newly diagnosed adult acute lymphoblastic leukemia (ALL). Blood 98:590a
Szatrowski TP, Dodge RK, Reynolds C, et al. (2003) Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B study 9311. Cancer 97:1471–1480
Thomas DA, Faderl S, Cortes J, et al. (2003) Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood [epub ahead of print]
Wassmann B, Gökbuget N, Scheuring UJ, et al. (2003) A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosomepositive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL). Ann Hematol 82:716–720
Gökbuget N, Raff R, Brügge-Mann M, et al. (2004) Risk/MRD adapted GMALL trials in adult ALL. Ann Hematol 83(Suppl 1): S129–131
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Faderl, S.H., Kantarjian, H.M. (2008). General Approach to the Therapy of Adult Acute Lymphoblastic Leukemia. In: Acute Leukemias. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72304-2_9
Download citation
DOI: https://doi.org/10.1007/978-3-540-72304-2_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-72302-8
Online ISBN: 978-3-540-72304-2
eBook Packages: MedicineMedicine (R0)